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Abstract
Schizophrenia  has  a  heterogeneous  and  complex  etiology  that  includes  multiple
candidate genes affected by a variety of mutational mechanisms including epigenetics,
functional  pathways,  and  environmental  factors.  This  chapter  mainly  focuses  on
reviewing two sets of studies. The first one is whole‐genome next‐generation sequenc‐
ing datasets involving monozygotic twins discordant for schizophrenia. The findings
suggest that de novo sequence variations may underlie the discordance of monozygotic
twins for schizophrenia. Second, whole‐genome DNA methylation study suggesting
the role of DNA methylation in the mechanisms of actions of antipsychotic drugs in
treating the disorder as well  as the manifestation of side effects such as metabolic
disorders. Furthermore, we are reporting original research results using next‐generation
mitochondrial DNA sequence analysis of a pair of monozygotic twins discordant for
schizophrenia as well as their mother. The chapter sheds light on the interplay between
sequence variations and epigenetic signatures, including DNA methylation changes, in
the  etiology  and  pathophysiology  of  schizophrenia.  Given  the  dynamic  nature  of
methylation, it may be possible to develop a new treatment strategy for schizophrenia
that is based on reversion of genomic methylation. This may involve environmental,
dietary, and/or pharmaceutical approaches.
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1. Introduction
The  treatment  of  schizophrenia  involves  the  suppression  of  hallucinations,  delusions,
agitation, and an array of behavioral problems that often accompany these symptoms [1].
When acute symptoms start to subside with antipsychotic drug treatment, psychotherapy and
rehabilitation  interventions  can  be  undertaken.  The  heterogeneity  of  schizophrenia  may
account for concentration of the disease in some families,  reduced concordance between
monozygotic  twins,  and patient‐specific  causations.  The identity  of  genes and pathways
involved in schizophrenia and the mechanisms affecting them are forthcoming. This devel‐
opment has identified important insights including the fact that a relatively large number of
genes affected in schizophrenia belong to relatively few critical pathways. This includes the
Dopamine  pathway  that  has  provided  the  foundation  for  the  development  of  primary
treatment of the disease. There is an opportunity to focus on additional affected pathways for
the treatment of a subset of patients. One of the mechanisms that may affect schizophrenia‐
related pathways is DNA methylation. This chapter will discuss primary molecular studies
that  support  a  threshold  model  for  this  complex  disease,  including  complete  genome
sequences of monozygotic twins discordant (MZD). Specifically, we identify patient‐specific
genes that may be affected by a variety of mutational mechanisms, including DNA methyla‐
tion. Here, the predisposition for the disease is realized on a threshold scale (Figure 1) via
mutations involving a variety of mechanisms including sequence variations and copy number
variations in nuclear genes as well as changes in genome‐wide DNA methylation [2, 3]. The
threshold model can only be tested on monozygotic twins discordant for the disease. Next,
we will argue for the direct role of DNA methylation in schizophrenia using two sets of
independent results; methylation differences between MZD twins and tissue‐specific response
of olanzapine (antipsychotic) treatment in rats in vivo [4, 5].
Figure 1. A threshold model for predisposition to schizophrenia in monozygotic twins discordant (MZD) for schizo‐
phrenia [2].
We will also discuss three facets of schizophrenia and their implications in the development
of any strategy for amelioration: (i) the role of de novo sequence variations (nuclear and mtDNA)
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in the etiology and treatment of psychiatric disorders, including schizophrenia; (ii) the
involvement of DNA methylation in the development of psychiatric disorders, particularly
schizophrenia; and (iii) the interplay between DNA sequence variation and DNA methylation.
The insights covered will be incorporated into the development of strategies toward person‐
alized medicine for the treatment of psychiatric disorders.
2. Role of sequence variations in the etiology and treatment of psychosis
A growing body of evidence suggests the significance of genetic variants in the etiology of
mental health disorders, including schizophrenia. For example, the Psychiatric Genomics
Consortium identified several SNPs that are associated with major psychiatric disorders
including schizophrenia [6], which included CACNA1C variants that have been previously
associated with autism [7]. Also, angiotensin‐converting enzyme (ACE) gene insertion/
deletion polymorphism was reported to be associated with schizophrenia susceptibility as well
as the severity of schizophrenia depressive symptoms in a Chinese population [8]. According
to the schizophrenia‐working group of the Psychiatric Genetic Consortium, the expression of
the C4 gene was affected by SNPs in the gene resulting in putative synapse elimination in
schizophrenia patients [9]. It has recently been reported that 15 of 48 schizophrenia cases were
found to carry rare or novel missense coding variants in four signaling genes studied. These
findings suggest that single genes harboring de novo mutations in individuals with psychosis
as compared to healthy controls may play a critical role in influencing the phenotypes of
psychosis and hence may be potential targets for developing treatment strategies. A study
from our lab reported that copy number variants (CNVs) in monozygotic twins discordant for
schizophrenia could be an important underlying factor in the discordance of the twins for the
disease [3]. The findings identified several CNVs and genes, in four of the six twin pairs
studied, that were previously implicated in mental health disorders. These findings suggest a
role for CNVs in the discordance of twins for schizophrenia.
Similarly, unpublished studies from our lab on complete genomes of two pairs of monozygotic
twins discordant for schizophrenia showed multiple individual sequence‐specific differences
between cotwins. The observed differences included small nucleotide changes (single nucleo‐
tide variation, block substitutions, and small indels), copy number variations, and structural
variations that were unique to either the affected or healthy cotwins. Also, by comparing the
sequence differences between cotwins with that of their parents, it was possible to identify de
novo variants. The study revealed several genes and gene‐networks that may have predisposed
the affected cotwins to the disease corroborating the fact that de novo variations between
cotwins may be an underlying factor for their discordance to the disease.
Due to the fact that there has been no single gene identified that is responsible for causing the
disorder, it is imperative that future research be focused on the polygenetic nature of schizo‐
phrenia, as well as the networks and pathways relevant to neurodevelopment and function.
A recent study identified genes and pathways associated with psychosis in 22q11.2 deletion
syndrome subjects [10]. The study revealed specific pathways affected in 22q11 deletion
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Syndrome carriers with psychosis and autistic spectrum disorders. Expression changes
associated with psychosis symptoms in 22q11 deletion syndrome was also associated with
pathways involved in transcriptional regulation. In addition, schizophrenia was reported to
be the only psychiatric disorder observed at a higher rate in 22q11 deletion syndrome com‐
pared to other neurodevelopmental disorders [11, 12].
The 22q11.2 deletion represents one of the most established genetic risk factors for the
development of psychiatric disorders. Our lab also reported the effect of DNA methylation in
the promoter regions of genes located in the microdeletion region on chromosome 22.
Accordingly, from a set of genes located in the 22q11.2 microdeletion region that has been
previously implicated in psychosis, 29 genes showed increased DNA methylation in their
promoters, following olanzapine treatment [13]. In that study, the effect of the antipsychotic
drug was revealed through significantly increased (p < 0.01) DNA methylation of genes
affecting several networks including neurological disease, inflammatory disease, inflamma‐
tory response, cancer, tumor morphology, and cell death and survival.
An increased number of studies suggest that rare genetic variations play an important role in
the genetic etiology of schizophrenia. However, the existence of rare genetic variations may
not always lead to the predisposition of schizophrenia. For example, a rare missense varia‐
tion in UCL13B was identified by whole‐exome sequencing, which was present in five of six
schizophrenia‐affected individuals but not in eight unaffected individuals [14]. In a follow‐up
case‐control study of two independent Japanese populations, there was no significant associ‐
ation between this missense variation and schizophrenia [14].
Chr Position Reference 
allele 
Sample
allele 
Variation
type 
Gene
regions 
Gene
symbol 
Sample
call
quality 
Sample read
depth in
G/H/F 
Translation
impact 
M  8701  A  G  SNV  Exonic  MT‐ATP6  255  600/680/611  Missense 
M  8860  A  G  SNV  Exonic  MT‐ATP6  255  336/367/322  Missense 
M  10819  A  G  SNV  Exonic  MT‐ND4  255  729/714/667  Synonymous 
M  10873  T  C  SNV  Exonic  MT‐ND4  255  613/662/573  Synonymous 
M  11719  G  A  SNV  Exonic  MT‐ND4  255  544/652/562  Synonymous 
Note: G/H/F: stands for healthy cotwin, affected cotwin, and their mom, respectively; Chr: chromosome.
Table 1. Mitochondrial single nucleotide variations detected in the discordant twins as well as their mother.
In addition to our analysis of nuclear DNA sequence variation, we have also conducted
mitochondrial DNA sequence analysis involving a pair of monozygotic twins discordant for
schizophrenia and their mother. Ingenuity Variant Analysis (Ingenuity System Inc, CA, USA)
identified no difference in the sequence variations between the discordant twins as well as their
mother. All of the biologically relevant variations detected were single nucleotide variations
(SNVs) in exonic regions of the MT‐ATP6 and MT‐ND4 genes (Table 1). The translational
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impact of the variation found in MT‐ATP6 was predicted to be missense while that of MT‐ND4
was predicted to be synonymous. All of the single nucleotide variations found in the mitochon‐
dria were detected in both of the twins and their mother. As we will discuss in the subsequent
sections, despite the identification of these biologically relevant sequence variations in all
samples, their interaction with epigenetic signatures including DNA methylation may differ
between individuals and lead to differences in susceptibility to disease.
Figure 2. The dotted line in purple shows the mean sequencing coverage of the mitochondrial genome for each sample.
(A) Healthy cotwin. (B) Schizophrenia‐affected cotwin. (C) Mother of the twins.
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Position Mutation Locus
10398 A>G MT‐ND3
10819 A>G MT‐ND4
10873 T>C MT‐ND4
11719 G>A MT‐ND4
12705 C>T MT‐ND5
14212 T>C MT‐CYB
1438 A>G MT‐RNR1
14766 C>T MT‐CYB
14905 G>A MT‐CYB
150 C>T MT‐DLOOP2
152 T>C MT‐DLOOP2
15301 G>A MT‐CYB
15326 A>G MT‐CYB
16172 T>C MT‐DLOOP1
16183 A>C MT‐DLOOP1
16189 T>C MT‐DLOOP1
16223 C>T MT‐DLOOP1
1647 T>C MT‐TV
16519 T>C MT‐DLOOP1
195 T>C MT‐DLOOP2
2352 T>C MT‐RNR2
263 A>G MT‐DLOOP2
2706 A>G MT‐RNR2
3316 G>A MT‐ND1
4769 A>G MT‐ND2
7028 C>T MT‐C01
73 A>G MT‐DLOOP2
750 A>G MT‐RNR1
8701 A>G MT‐ATP6
8860 A>G MT‐ATP6
9540 T>C MT‐C03
Table 2. Homoplasmies detected in the discordant twins and their mother.
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We used mtDNA‐server [15] to identify heteroplasmies. All sites with a log likelihood ratio
(LLR) of ≥5 were considered as heteroplasmic sites. This analysis did not identify any hetero‐
plasmies in our samples. Among other reasons, the sequencing coverage may have affected
our ability to detect heteroplasmies in the present samples (Figure 2). Coverage of ≥10× fold
per strand is required on both the forward and reverse strand to accurately identify hetero‐
plasmic sites [15]. We believe that better coverage would more accurately identify heteroplas‐
mies that may have a role in the etiology of schizophrenia. Furthermore, analyzing larger
samples may help investigate heteroplasmies and their association with schizophrenia; as it is
possible that each patient could signify a specific etiology and pathophysiological manifesta‐
tion of the disease via his/her unique genetic makeup and epigenomic signature. In another
study, novel and rare nonsynonymous mutations were identified in mtDNA genes (ND6,
ATP6, CYTB, and ND2) in subjects with psychiatric disorders [16]. The authors also reported
mtDNA heteroplasmy at a locus that was known to be associated with schizophrenia
(T16519C). The homoplasmies detected in the aforementioned sample of a pair of twins
discordant for schizophrenia and their mother are presented in Table 2.
3. The role of DNA methylation in the development of psychosis
DNA methylation represents a core epigenetic mechanism that involves the covalent binding
of a methyl group to the 5‐carbon position of cytosine, often leading to altered gene expression
[17]. DNA methylation is influenced by stochastic events, including exposure to a variety of
environmental factors, such as drug treatment [18, 19]. Epigenetic mechanisms, including
DNA methylation, regulate normal cognition, neurodevelopment, and function. In addition,
DNA sequence variations only explain a small proportion of the heritability of the disease. The
remaining heritability, often referred to as missing heritability, could be, at least partially,
explained by epigenetic changes. Interestingly, a number of animal model studies of neuro‐
developmental disorders signified that reversing the underlying molecular deficits could lead
to substantial improvements in function giving hope to effective treatments even starting in
adulthood [20]. These points highlight the need to further investigate the role of epigenetic
signatures in the etiology and treatment of psychiatric disorders, including schizophrenia.
With this in mind, our lab has performed two sets of studies on DNA methylation in schizo‐
phrenia. The first study focused on two pairs of monozygotic twins discordant for schizo‐
phrenia and their parents to investigate differences in genome‐wide DNA methylation using
a NimbleGen Methylation Promoter Microarray. Since monozygotic twins share nearly
identical DNA, the study represents an ideal design to investigate the role of DNA methylation
in the etiology of the disease. The genomic DNA was processed at ArrayStar (Rockville, MD,
USA). Pair files were analyzed with the tiling workflow in Partek Genomics Suite version 6.6
(St. Louis, Missouri, USA). Details of the methodology have been previously described [4]. As
a result, differentially methylated regions (DMRs) were identified between discordant
monozygotic twins. Some of the DMRs were shared with parents of the discordant twins while
others represented de novo methylation changes [4]. The study also reported that 27 genes were
affected by DMR changes that were commonly detected in the schizophrenia‐affected member
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of the two discordant monozygotic pairs of unrelated families. Many of these genes were found
to be a part of the histone coding gene family, which has been previously linked to the causation
of schizophrenia [21–23]. Moreover, the identified genes affected by DMRs were linked to
specific networks including “cell death and survival” and “cellular movement and immune
cell trafficking” [4]. Interestingly, those genes and their networks have been previously
associated with the etiology of schizophrenia. The findings of this particular study corrobo‐
rated the notion that DNA methylation may play a critical role in the discordance of mono‐
zygotic twins for schizophrenia. The results also shed light on the relevance of gene‐specific
DNA methylation changes and on the involvement of multiple genes harboring methylation
changes across specific pathways in the discordance of monozygotic twins for schizophrenia.
The second study comprised an animal model experiment investigating genome‐wide DNA
methylation changes following the administration of a therapeutic dose of olanzapine in rats
in vivo. Hippocampus and cerebellum brain regions were used and liver was included as a
nonbrain tissue [5]. As a result, our study revealed that DNA methylation is not only involved
in the etiology of mental health disorders, but also may be the underlying mechanism by which
antipsychotic drugs function in treating the disorder. This was supported by a number of
pathways significantly influenced by methylation changes. These included “nervous system
development and function, tissue morphology, cellular assembly and organization,” (Fig‐
ure 3). These findings suggested that an increase or decrease in DNA methylation of specific
gene promoters, following olanzapine treatment, might decrease or increase transcriptional
efficiency [37, 38], specifically in the hippocampus. The hippocampus is viewed as one of the
primary sites associated with psychotic symptoms [7, 24, 25]. We also reported that the
dopamine‐DARPP32 feedback in cAMP signaling pathway (p < 1.6E‐3) was the most significant
pathway identified in the hippocampus region of the olanzapine‐treated rat brain. Neurons in
the midbrain release dopamine, which modulates cAmp (cyclic adenosine 3,5‐monophosphate)
production by activating dopamine receptors [1]. These results may suggest that antipsychotic
effects of olanzapine involve alterations in gene‐specific methylation that would lead to dis‐
regulation of genes involved in the dopamine DARPP32 feedback in cAmp signaling pathway.
This includes several differentially methylated genes such as Drd1/5 and Nos1. It is an estab‐
lished fact that dopamine blockade leads to the progressive treatment of psychosis while its
disturbance leads to the manifestation of psychosis [26]. And, all currently used antipsychotics
block postsynaptic D2 receptors [27].
Schizophrenia patients either partially respond to antipsychotic drugs or do not respond at all
[28]. This may be due to several factors, and one possibility is the delay in the onset of
therapeutic actions partly or fully influenced by downstream effects, such as altered tran‐
scription [29, 30]. As such, differentially methylated genes involved in the dopamine‐signaling
pathway may stop or reduce transcription and gene expression [17, 29, 30].
Significant hypomethylation in two CpG sites of the FAM63B gene in bipolar disorder patients
have been recently reported [31]. Their findings plus previous hypomethylation results
reported in another study involving schizophrenia patients suggest that FAM63B may be a
common risk gene for both disorders. Although the authors reported correlation in methyla‐
tion levels at the two sites, they did not find significant association of DNA methylation with
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Figure 3. (A) Nervous system development and function, tissue morphology, cellular assembly and organization. (B)
Metabolic disease, tissue morphology, endocrine system disorders. Genes shaded in gray were affected by changes in
promoter methylation [5].
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nearby SNPs, which may further corroborate the biological significance of identifying epige‐
netic signatures in addition to conducting genome‐wide association analyses. On their own,
association analyses will not always reveal risk variants or genes due to their limitations such
as low statistical power or the presence of genotyping error as well as the detection of false
positives.
Different brain regions as well as a variety of cell types are known to have different epige‐
netic signatures, and depending on the subpopulations analyzed, specific cell types may
even show different epigenetic signatures within their own subpopulation [32, 33]. These
reported differences in epigenetic signatures of different brain regions and our observa‐
tions of significant differences in DNA methylation patterns of hippocampus and cerebel‐
lum in a rat model study, reflect the possibility that these epigenetic signatures may play a
role in regulating gene expression and thereby causing psychiatric disorders including
schizophrenia.
Several CpGs have been reported to show significant differences in DNA methylation levels
in psychosis cases [34]. These results shed light on the significance of epigenetic signatures in
the causes and treatment of mental health disorders. Our previous studies revealed brain
tissue‐specific DNA methylation changes [5]. As a result, scientists are now advising for
caution when interpreting the findings of DNA methylation differences in schizophrenia
affected and healthy subjects using peripheral tissues, including blood samples [35].
As we noted in our previous reports, olanzapine caused an increase or a decrease in methyl‐
ation of genes previously implicated in schizophrenia, which may reflect the fact that olanza‐
pine could result in the recovery of psychiatric symptoms via mechanisms involving DNA
methylation. Among the genes that showed a decrease in methylation in hippocampus is
Map6, which is implicated in schizophrenia [36], and involved in molecular transport, nervous
system development, and function [5]. This implies that methylation may serve an interme‐
diary role whose actual effect is realized through gene expression.
Apart from the involvement of DNA methylation in the treatment of schizophrenia via
antipsychotic administration, methylation changes may also affect genes and pathways that
reflect the side effects of the drugs. In a genome‐wide assessment, our studies showed
methylation changes in several genes and pathways that may alter metabolomics leading to
the efficacy as well as side effects of olanzapine. The side effects were reflected by significant
increases in body weight gain and a pathway affecting metabolic disorders. Interestingly,
genetic variations in various genes including BDNF have been implicated in antipsychotic‐
induced weight gain [37]. However, the relationship between sequence variations and
methylation changes in leading to the predisposition of individuals to the disease, their role
in the efficacy of antipsychotic treatment, and also their role in the side effects of the drugs
remains to be investigated.
It is an established fact that genomic imprinting is an epigenetic phenomenon by which
certain genes are expressed in a parent‐of‐origin specific manner [38]. Also, X‐chromosome
inactivation invariably involves epigenetic phenomenon [39, 40]. The genomic distributions
of epimutations play an important role in their effects on the disorder. In particular, we
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would like to emphasize that not all observed epigenetic changes in the genome play a role
in the regulation of gene expression. Although most epimutations located in nonpromoter
regions do not often lead to changes in gene expression, epigenetic signatures in the pro‐
moter regions are often associated with regulation of gene expressions [29, 41]. Interesting‐
ly, long‐lasting alterations in DNA methylation and their effect on neurodevelopmental
disorders have been reported [42]. However, changes in DNA methylation needs to be in‐
terpreted with caution, as methylation and its function are context‐dependent [43]. More
importantly, effects of epimutations on neurodevelopmental disorders are tissue‐specific,
cell‐type, and organ specific [44, 45]. Interestingly, our lab reported tissue‐specific changes
in promoter DNA methylation of several psychosis related genes using hippocampus, cere‐
bellum, and liver samples [5].
Overall, the results from our lab and elsewhere suggest that aberrant DNA methylation in a
set of candidate genes may be involved in mental disorders, including schizophrenia [46]. Also,
it may explain the therapeutic efficacy, side effects, and individual specificity of responses to
antipsychotic treatments. They may result from changes in tissue‐specific DNA methylation
in a set of genes [5, 13, 47, 48]. However, DNA methylation changes in mental health patients
and their effects on the expression of psychosis relevant genes as well as the development of
psychotic symptoms require attention in future studies. Also, effects of DNA methylation on
the expression of specific sets of genes leading to the development of schizophrenia, requires
further investigation. To this effect, the use of endophenotypes (intermediate phenotypes that
are quantifiable traits of the disease) may help facilitate the investigation of the underlying
biological basis of schizophrenia. The United States Food and Drug Administration has
accepted endophenotypes as therapeutic treatment targets [49]. Further, our study based on
two sets of studies (a rat model investigating effects of olanzapine on DNA methylation of
brain regions, and monozygotic twins discordant for schizophrenia) revealed genes and gene
networks commonly affected in the two sets of studies. The findings reflect the fact that a
considerable portion of the observed methylation changes are likely to be caused by antipsy‐
chotic drugs in both studies [50]. Also, it is likely that some of the methylation changes seen
can be attributed to the underlying factors that predispose patients to the disorder. Further
studies are still needed to confirm the role of methylation changes in the etiology and patho‐
physiology of the disease.
4. Interplay between DNA sequence variation and DNA methylation
The role of DNA methylation in gene regulation and the interplay between genomic sequence
variations and various environmental features as well as their implications on disease pheno‐
types remains to be investigated. However, studies support the role of DNA methylation in
regulatory interactions influencing gene expression [51]. It is also established that there is an
interplay between sequence variation, DNA methylation, and gene expression [52]. A recent
study has highlighted the fact that mutated CpG sites (CpG‐SNPs) could play a critical role in
the cause and treatment of the disease [34].
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Our lab recently identified several genes that differ between the affected and unaffected
members of two monozygotic twin pairs discordant for schizophrenia. The differences were
assessed using a genome‐wide methylation promoter array and complete genome sequen‐
ces. The results shed light on a number of facts. First, monozygotic twins differ in both DNA
methylation as well as de novo sequence variations. Antipsychotic drugs could have caused
the observed DNA methylation changes as was evidenced in our rat model study discussed
above. Also, there is a possibility that DNA methylation changes could be caused by de novo
events. It has been reported that differences in genetic components underlie the differences
in DNA methylation profiles observed between individuals [53]. Second, some genes that
were affected by differential promoter methylation between discordant monozygotic twins
also harbor a number of different types of sequence variations [2]. Some of the variations
may represent de novo sequence variations. Third, a number of the observed changes are
located in known candidate genes for schizophrenia. Thus, the genes harboring promoter
DNA methylation changes could contribute to neuropsychiatric disorders, including schizo‐
phrenia. Moreover, when the DNA sequence differences were analyzed independently, ad‐
ditional previously reported candidate genes of schizophrenia were identified (unpublished
data) suggesting that these findings may reflect that many of the previously identified can‐
didate genes of schizophrenia can be revealed by differences in DNA sequence. These find‐
ings also highlight the patient‐specific nature of these differences. Any sequence variation or
promoter DNA methylation between a patient and their healthy cotwin was considered as a
potential predisposing factor for the disease. Overall, the findings to date argue that it is not
only sequence variation but also their interactions with chromatin structure and other epige‐
netic signatures which regulate disease outcomes. Therefore, future studies need to focus on
investigating the interactions of sequence variation, including nuclear and mitochondrial
DNA sequence variations, with epigenetic signatures, in subjects with psychosis and
healthy controls.
Studies in the past support the notion that DNA methylation may play a critical role in the
therapeutic efficacy of olanzapine. For example, findings suggest that DNA methylation
changes in the promoter regions of several genes including genes located in the 22q11.2
microdeletion region and the cadherin/protocadherin genes impact the response of olanzapine
treatment [47]. These impacts have been revealed through the identified pathways that have
been previously implicated in psychosis.
In conclusion, the results from our lab and elsewhere corroborated the fact that various types
of de novo sequence, including copy number variants and their interactions with epigenetic
signatures, may underlie the etiology of schizophrenia and also may hold the key to discovery
of drug targets in developing personalized medicine for psychosis. Epigenetic changes, DNA
methylation in particular, may play a critical role in the therapeutic efficacy of antipsychotic
drugs. Overall, the known functions of genes affected by olanzapine‐induced DNA methyla‐
tion changes suggest that DNA methylation differences may underlie the amelioration of
psychosis symptoms as well as account for certain adverse effects of drugs used to treat the
disorder.
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